Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06620042 · ClinicalTrials.gov registry record · Phase 2
FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression
A Phase 2 study of Bipolar Depression and Treatment-resistant Bipolar Depression, sponsored by Brian Barnett.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT06620042: Completed Phase 2 study of Bipolar Depression and Treatment-resistant Bipolar Depression, sponsored by Brian Barnett.
NCT06620042 is a Phase 2 study of Bipolar Depression and Treatment-resistant Bipolar Depression that has completed, run by Brian Barnett. The registered enrollment target is 20 participants, below the 215-participant average among 29 other Bipolar Depression trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06620042, a Phase 2 study of Bipolar Depression and Treatment-resistant Bipolar Depression, has completed, sponsored by Brian Barnett.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective open-label observational study of patients with treatment resistant bipolar depression referred for intravenous ketamine, with an interventional component of fMRI.
Primary Outcome
Seed-to-whole brain functional connectivity z-maps will be calculated from the left and right subgenual cingulate on the baseline and post-acute resting-state functional MRI (rs-fMRI) from each participant. After acute treatment, participants will be categorized as "responders" (≥50% decrease from baseline score of Quick Inventory of Depressive Symptomatology 16-item self-report, QIDS-SR-16) or "non-responders". Brain regions in responders that exhibit significantly different treatment-related c
Conditions Studied
Interventions
- DRUG Ketamine
- OTHER Functional magnetic resonance imaging (fMRI)
Study Locations (2)
Ohio
- Cleveland Clinic Lutheran Hospital - Cleveland
- Cleveland Clinic Lutheran Hospital - Ohio City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-11-12 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 2 |
What the finished NCT06620042 record still lists
NCT06620042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 215-participant average among 29 other Bipolar Depression trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Bipolar Depression appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT06620042 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06620042 about?
NCT06620042 is a clinical study titled "FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression". This is a prospective open-label observational study of patients with treatment resistant bipolar depression referred for intravenous ketamine, with an interventional component of fMRI.
What is the current status of trial NCT06620042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-11-12. Estimated completion is 2025-10-31.
What conditions does trial NCT06620042 study?
This clinical trial studies the following conditions: Bipolar Depression, Treatment-resistant Bipolar Depression.
What interventions are being tested in trial NCT06620042?
The interventions under investigation include: Ketamine (DRUG), Functional magnetic resonance imaging (fMRI) (OTHER).
Who is sponsoring clinical trial NCT06620042?
This trial is sponsored by Brian Barnett, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06620042 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06620042's enrollment target sits among peer trials
20 22nd of 29 higher than 3 of 29 other Bipolar Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression
COMPLETED · Phase 2
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
RECRUITING · Phase 3
-
University of Iowa Interventional Psychiatry Service Patient Registry
RECRUITING
-
Ketogenic Intervention for Bipolar Depression
RECRUITING · NA
-
RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI